



# TODT HILL PHARMACY

SPECIALTY PHARMACY

2110 Richmond Road  
Staten Island, NY 10306

Toll Free 844.994.0016  
Phone 718.351.7363  
Fax 718.351.4972  
www.todthillspecialtyrx.com  
todthillrx@gmail.com

## GOUT

### PATIENT INFORMATION

Please provide physical address, NO PO boxes

NAME (FIRST, ML, LAST) \_\_\_\_\_  
ADDRESS \_\_\_\_\_  
CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_  
PHONE \_\_\_\_\_ EMAIL \_\_\_\_\_  
GENDER  MALE  FEMALE PRIMARY LANGUAGE \_\_\_\_\_  
DATE OF BIRTH \_\_\_\_\_ HEIGHT \_\_\_\_\_ WEIGHT \_\_\_\_\_  
ALTERNATE CONTACT \_\_\_\_\_ RELATIONSHIP \_\_\_\_\_  
PHONE \_\_\_\_\_ EMAIL \_\_\_\_\_

PATIENT

**SIGNATURE** \_\_\_\_\_ DATE \_\_\_\_\_

REQUIRED

### INSURANCE INFORMATION

Please attach front and back of all insurance cards

PLAN NAME \_\_\_\_\_ PHONE \_\_\_\_\_  
IID NUMBER \_\_\_\_\_ GROUP NUMBER \_\_\_\_\_

#### SECONDARY INSURANCE

PLAN NAME \_\_\_\_\_ PHONE \_\_\_\_\_  
IID NUMBER \_\_\_\_\_ GROUP NUMBER \_\_\_\_\_

### PHYSICIAN INFORMATION

NAME (FIRST, ML, LAST) \_\_\_\_\_ SPECIALTY \_\_\_\_\_  
PRACTICE NAME \_\_\_\_\_ OFFICE CONTACT \_\_\_\_\_ OFFICE PHONE \_\_\_\_\_  
ADDRESS \_\_\_\_\_ EMAIL \_\_\_\_\_  
CITY \_\_\_\_\_ STATE \_\_\_\_\_ ZIP \_\_\_\_\_ LICENCE # \_\_\_\_\_ NPI # \_\_\_\_\_  
PHONE \_\_\_\_\_ EMAIL \_\_\_\_\_ TAX ID # \_\_\_\_\_  
REFERRING PHYSICIAN \_\_\_\_\_ SPECIALTY \_\_\_\_\_

PHYSICIAN

**SIGNATURE** \_\_\_\_\_ DATE \_\_\_\_\_

REQUIRED

### DIAGNOSIS AND CONTRAINDICATION

PRIMARY DIAGNOSIS  M1A    - CHRONIC GOUT\*

\* USE CHRONIC GOUT ICD -10 CODES WHEEL IN REIMBURSEMENT KIT OR SEE THE FULL LIST OF THE MOST CURRENT CODES AT [www.CHRONICGOUTCODES.COM](http://www.CHRONICGOUTCODES.COM)

YES  NO DOES THE PATIENT HAVE A DIAGNOSIS OF A SYMPTOMATIC HYPERURICEMIA OR A DEFICIENCY IN G6PD

**IF YES, PATIENT IS NOT A CANDIDATE FOR KRYSTEXXA**

\*ASYMPTOMATIC HYPERURICEMIA IS DEFINED AS ELEVATED URIC ACID LEVEL (>6.8 mg/dl) IN PATIENTS WHO HAVE NEVER EXHIBITED SIGNS OR SYMPTOMS OF GOUT (EG, GOUT FLARE, TOPHI)  
G6PD= GLUCOSE-6-PHOSPHATE DEHYDROGENASE

**DOSE: 8 mg EVERY 2 WEEKS, NDC: 75987-0080-10**

IS THIS FOR INITIATION OR CONTINUATION OF THERAPY?

INITIATION

CONTINUATION

DATE OF 1st INFUSION \_\_\_\_/\_\_\_\_/\_\_\_\_ DURATION of TREATMENT \_\_\_\_\_ ORIGINAL START DATE \_\_\_\_/\_\_\_\_/\_\_\_\_ LAST INFUSION DATE \_\_\_\_/\_\_\_\_/\_\_\_\_  
(mm/dd/yyyy) (mm/dd/yyyy) (mm/dd/yyyy)

**CURRENT SYMPTOMS**

WHAT IS THE PATIENT'S MOST RECENT SUA LEVEL AND DATE OBTAINED?

\_\_\_\_\_mg/dL, DATE OBTAINED: \_\_\_\_/\_\_\_\_/\_\_\_\_  
(mm/dd/yyyy)

YES  NO DOES PATIENT HAVE KIDNEY DYSFUNCTION?

IF YES, GFR \_\_\_\_\_ SERUM CREATININE \_\_\_\_\_

YES  NO IS THERE EVIDENCE OF A TOPHUS?

IF YES, HOW MANY: \_\_\_\_\_

YES  NO HAS THE PATIENT UNDERTAKEN APPROPRIATE LIFESTYLE MODIFICATIONS?

IF YES, PLEASE CHECK ALL THAT APPLY

YES  NO IS THERE EVIDENCE OF GOUTY ARTHRITIS?  
(TENDER AND SWOLLEN OR LESIONED JOINTS)

IF YES, HOW MANY JOINTS ARE IMPACTED? \_\_\_\_\_

DISCONTINUING OR CHANGING MEDICATIONS THAT ARE KNOWN TO PRECIPITATE GOUT ATTACKS

YES  NO HAS THE PATIENT EXPERIENCED FUNCTIONAL IMPAIRMENT?

IF YES, PLEASE DESCRIBE: \_\_\_\_\_

IMPLEMENTING DIET CHANGES (CONSUME LOW-PURINE DIET, REDUCE REFINED CARBOHYDRATES, LIMIT MEATS, INCREASE VEGETABLES AND FRUIT)

DECREASING ALCOHOL CONSUMPTION

YES  NO HAS THE PATIENT EXPERIENCED 3 OR MORE FLARES IN THE PAST 18 MONTHS?

IF NO, HOW MANY FLARES HAS THE PATIENT EXPERIENCED IN THE PAST 18 MONTHS? \_\_\_\_\_

LIMITING DRINKS RICH IN FRUCTOSE

UNKNOWN

OTHER

IF YES, PLEASE PROVIDE MOST RECENT DATES \_\_\_\_/\_\_\_\_/\_\_\_\_ \_\_\_\_/\_\_\_\_/\_\_\_\_ \_\_\_\_/\_\_\_\_/\_\_\_\_  
(mm/dd/yyyy) (mm/dd/yyyy) (mm/dd/yyyy)

SUN = SERUM URIC ACID

**ORAL URATE LOWERING TREATMENT HISTORY**

TREATMENT	PATIENT AT MAX MEDICALLY APPROPRIATE DOSE	MAX DOSE	START DATE	END DATE	SUA AT END OF TREATMENT	EXPLAIN OUTCOME OR SPECIFY CONTRAINDICATION	PATIENT IS CONTRAINDICATED
ALLOPURINOL							<input type="checkbox"/>
FEBUXOSTAT							<input type="checkbox"/>
PROBENECID/ LESINURAD/ <small>(circle or write in uricosuric)</small>							<input type="checkbox"/>

YES  NO WILL ORAL URATE - LOWERING TREATMENTS BE DISCONTINUED BEFORE STARTING KRSTEXXA?

PATIENTS SHOULD DISCONTINUE ORAL URATE-LOWERNG TREATMENTS BEFORE STARTING KRSTEXXA

I VERIFY THAT THE PATIENT AND HEALTHCARE PROVIDER INFORMATION ON THIS ENROLMENT FORM WAS COMPLETED BY ME OR AT MY DIRECTION AND THAT THE INFORMATION CONTAINED HEREIN IS COMPLETE AND ACCURATE TO THE BEST OF MY KNOWLEDGE

PHYSICIAN  
**SIGNATURE** \_\_\_\_\_ DATE \_\_\_\_\_  
 REQUIRED

PLEASE READ PHYSICIAN AUTHORIZATION ON PAGE 3